Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Nov 7;12(1):18929.
doi: 10.1038/s41598-022-21797-x.

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Yurie Kobashi  1   2 , Takeshi Kawamura  3   4 , Yuzo Shimazu  1 , Tianchen Zhao  1 , Akira Sugiyama  3 , Aya Nakayama  3 , Yudai Kaneko  4   5 , Yoshitaka Nishikawa  2 , Fumiya Omata  2 , Morihito Takita  1   6 , Chika Yamamoto  1   7 , Makoto Yoshida  6 , Makoto Kosaka  6 , Anju Murayama  6 , Sota Sugiura  6 , Manato Tanaka  6 , Moe Kawashima  1 , Yuna Uchi  1 , Joji Shindo  8 , Tomoyoshi Oikawa  9 , Kenji Shibuya  1   10   11 , Tatsuhiko Kodama  4 , Masaharu Tsubokura  12   13   14   15   16
Affiliations
Observational Study

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Yurie Kobashi et al. Sci Rep. .

Abstract

To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale community based cohort.

Methods: Participants in the observational cross-sectional study received a second dose of vaccination with BNT162b2 (Pfizer/BioNTech) and were not previously infected with COVID-19. Questionnaire-collected data on sex, age, adverse vaccine reactions, and medical history was obtained.

Results: Data from 2496 participants revealed that older age groups reached a low antibody titer 90-120 days after the second vaccination. Neutralizing activity decreased with age; 35 (13.3%) of those aged ≥ 80 years had neutralizing activity under the cut-off value. Neutralizing activity > 179 days from the second vaccination was 11.6% compared to that at < 60 days from the second vaccination. Significantly lower IgG antibody titers and neutralizing activity were associated with age, male sex, increased time from second vaccination, smoking, steroids, immunosuppression, and comorbidities.

Conclusions: Antibody titer decreased substantially over time. Susceptible populations, older people, men, smokers, steroid users, immunosuppression users, and people with three or more comorbidities may require a special protection strategy.

PubMed Disclaimer

Conflict of interest statement

Kaneko is employed by Medical & Biological Laboratories, Co., (MBL, Tokyo, Japan). MBL imported the testing material used in this research. Kaneko participated in the testing process; however, he did not engage in the research design and analysis. Kobashi and Tsubokura received a research grant from Pfizer Health Research Foundation for research not associated with this work. The remaining authors declare no potential conflict of interest.

Figures

Figure 1
Figure 1
Requirement of participants. The participants were mainly recruited from rural Fukushima prefecture, including health care workers, frontline workers, administrative officers, general residents, and residents of long-term care facilities.
Figure 2
Figure 2
Distribution of (a) IgG antibody titer against S1 protein and (b) neutralizing activity by age groups. Anti-S1 IgG antibody and neutralizing activity were log-transformed. The cut-off values of each antibody were 10 arbitrary units per milliliter (AU/mL).
Figure 3
Figure 3
Distribution of (a) IgG antibody titer against S1 protein and (b) neutralizing activity by groups based on duration from second vaccination. Anti-S1 IgG antibody and neutralizing activity were log-transformed. The cut-off values of each antibody were 10 arbitrary units per milliliter (AU/mL). The adjusted mean titer was calculated using the age distribution of the whole country’s population based on the Japanese model population in 1985 (we do not have the new version of the model population).
See this image and copyright information in PMC

References

    1. Alfano G, et al. One-year persistence of neutralizing anti-SARS-CoV-2 antibodies in dialysis patients recovered from COVID-19. Hemodial. Int. 2021;25:E53–E56. doi: 10.1111/hdi.12963. - DOI - PMC - PubMed
    1. Le Bert N, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z. - DOI - PubMed
    1. Goldberg Y, et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 2021;385:e85. doi: 10.1056/NEJMoa2114228. - DOI - PMC - PubMed
    1. Tartof SY, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet. 2021;398:1407–1416. doi: 10.1016/S0140-6736(21)02183-8. - DOI - PMC - PubMed
    1. Israel A, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. medRxiv. 2021 doi: 10.1101/2021.08.19.21262111. - DOI - PMC - PubMed

Publication types

Grants and funding